Market Research Logo

Global Glioblastoma Multiforme Therapeutics Market 2015-2019

Global Glioblastoma Multiforme Therapeutics Market 2015-2019

About Glioblastoma Multiforme

Glioblastoma multiforme is the most aggressive variant of malignant brain cancer. It has a poor prognosis with low rate of survival, a median of one year. The primary brain tumor happens due to uncontrolled cell division and developments in the brain. The tumors can be found in the glial cells or the neuron. The one which develops in the glial cells (astrocytes and oligodendrocytes) is called glioma, the commonest forms of brain tumor.

Glioblastoma multiforme is the most common variant of brain tumor, and highly invasive in nature. It may turn up in the cerebrum, mostly in the frontal and temporal lobes, and seldom spreads in areas outside the brain. The tumor progresses rapidly, and is among the most difficult-to-treat cancer with limited treatment options.

Glioblastoma multiforme is also known as Class IV astrocytoma which has an unknown etiology, and is more frequent in men than women. Some of the common symptoms of glioblastoma multiforme are increased intracranial pressure resulting in nausea, vomiting, and headache, cognitive and visual impairment, motor dysfunction, seizures, loss in sensory functions, and changes in personality, mood or concentration. The condition can be broadly classified into two types, primary or de novo glioblastoma multiforme (which progresses very fast) and secondary glioblastoma multiforme (which is known to progress at a slower rate). Glioblastoma multiforme can be treated by chemotherapy, steroids, radiation therapy, proton therapy, surgical procedure, and immunotherapies, which are the emerging treatment options yet to hit the market.

Technavio analysts forecast the global glioblastoma multiforme therapeutics market to grow at a CAGR of 11.94 percent during 2014-2019.

Covered in this Report

The report covers the present scenario and the growth prospects of the global glioblastoma multiforme therapeutics market for the period 2015-2019. To calculate the market size, we consider revenue generated from the sales of various off-label and branded drugs and the expected launch of vaccines and drug candidates used in the treatment of glioblastoma multiforme.

Based on the route of administration of the drugs used to treat glioblastoma multiforme, the market is segmented as follows:

  • Oral
  • Parenteral
Based on the type of molecules of the drugs used to treat glioblastoma multiforme, the market is segmented as follows:
  • Small Molecules
  • Biologics
This report includes a discussion on the market in the following three regions:
  • The Americas: The major countries focused in the Americas are the US, Canada, Mexico, and Brazil
  • EMEA: The major countries in this region are the UK, Germany, Italy, France, Spain and Middle Eastern and African countries, such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
  • APAC: The major countries in this region are Japan, China, Australia, Singapore, South Korea, and India
Technavio also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. The vendor landscape includes a market share analysis of the major vendors along with the performances of their product portfolios. In addition, we discuss the major drivers influencing market growth and also outlines the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market.

The Technavio report, namely Global Glioblastoma Multiforme Therapeutics Market 2015-2019, is based on an in-depth market analysis, with inputs from industry experts. The report covers the Americas, and EMEA and APAC markets. It presents the market landscape and its growth prospects in the coming years.Key Regions
  • Americas
  • EMEA
  • APAC
Key Vendors
  • Arbor Pharmaceuticals
  • Bristol-Myers Squibb
  • Eisai
  • F. Hoffmann-La Roche
  • Merck
Other Prominent Vendors
  • AB Science
  • Abbvie
  • Actelion
  • Activartis Biotech
  • Advantagene
  • Agenus
  • Agios
  • Amgen
  • Angiochem
  • Apogenix
  • Axelar
  • BioNTech
  • Boehringer Ingelheim
  • Boston Biomedical
  • Bristol-Myers Squibb
  • Celgene
  • Celldex Therapeutics
  • ChemoCentryx
  • Cortice Biosciences
  • CytoVac
  • CytRx
  • Deciphera
  • Del Mar Pharmaceuticals
  • Diffusion Pharmaceuticals
  • DNATrix
  • Eli Lilly
  • Epitopoietic Research
  • e-Therapeutics
  • Exelixis
  • G W Pharmaceuticals
  • Genspera
  • immatics
  • ImmunoCellular Therapeutics
  • Immunovaccine
  • Intrexon
  • IRAD Oncology
  • Karyopharm Therapeutics
  • Kite Pharma
  • Life Science Pharmaceuticals
  • Medicenna Therapeutics
  • Merck
  • Merrimack Pharmaceuticals
  • Nektar Therapeutics
  • Northwest Biotherapeutics
  • Novartis
  • Noxxon
  • OncoSynergy
  • Oncovir
  • Ono Pharmaceutical
  • Peregrine Pharmaceuticals
  • Plexxikon
  • Sanofi
  • Seattle Genetics
  • Spectrum Pharmaceuticals
  • Stemline Therapeutics
  • Tocagen
  • Tracon Pharma
  • TVAX Biomedical
  • VBL Therapeutics
  • Virttu Biologics
  • Ziopharm Oncology
Market Driver
  • Lack of Treatment Options for Glioblastoma Multiforme
  • For a full and detailed list, view our report
Market Challenge
  • Use of Off-label Drugs
  • For a full and detailed list, view our report
Market Trend
  • Prospective Entry of Novel Agents
  • For a full and detailed list, view our report
Key Questions Answered in this Report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Glioblastoma Multiforme Therapeutics Market 2015-2019

Technavio recognizes the following companies as the key players in the Global Glioblastoma Multiforme Therapeutics Market: Arbor Pharmaceuticals LLC, Bristol-Myers Squibb Co., Eisai Co. Ltd., F. Hoffmann-La Roche Ltd. And Merck & Co. Ltd.

Commenting on the report, an analyst from Technavio’s team said: “The entry of novel therapeutic agents to treat glioblastoma multiforme is a major trend witnessed in the market. The drugs which are currently being used are mostly chemotherapeutic agents that are usually toxic to the cells of the body. These drugs are known to also harm the non-cancerous cells besides destroying the malignant cells.”

According to the report, the market is expected to grow because of the presence of significant unmet need. This presents an opportunity to the drug makers to develop a therapy to treat glioblastoma multiforme with better efficacy and safety parameters. This in turn will reduce the rate of treatment withdrawal by patients, which would be a positive indicator of growth to the market.

Further, the report states that market growth may be hampered because of use of off-label and generic drugs over the branded drugs available in the market. Most of the branded drugs have either lost their patent or will lose their patent during the forecast period.

  • Executive Summary
  • List of Abbreviations
  • Scope of the Report
    • Market Overview
    • Product Offerings
  • Market Research Methodology
    • Market Research Process
    • Research Methodology
      • Table Market Research Methodology
  • Introduction
  • Market Landscape
    • Global Glioblastoma Multiforme Therapeutics Market
      • Market Overview
        • Table Snapshot of the Global Glioblastoma Multiforme Therapeutics Market
      • Market Size and Forecast
        • Table Global Glioblastoma Multiforme Therapeutics Market 2014-2019 ($ millions)
        • Table Key Takeaways: Global Glioblastoma Multiforme Therapeutics Market
    • Five Forces Analysis
  • Market Segmentation by Route of Administration
    • Table Segmentation of Global Glioblastoma Multiforme Therapeutics Market by Route of Administration
    • Oral
    • Parenteral
  • Market Segmentation by Type of Molecule
    • Table Segmentation of Global Glioblastoma Multiforme Therapeutics Market by Type of Molecule
    • Small Molecules
    • Biologics
  • Geographical Segmentation
    • Table Segmentation of Global Glioblastoma Multiforme Therapeutics Market by Geography 2014
    • Glioblastoma Multiforme Therapeutics Market in Americas
      • Market Overview
      • Market Size and Forecast
        • Table Glioblastoma Multiforme Therapeutics Market in Americas 2014-2019 ($ millions)
    • Glioblastoma Multiforme Therapeutics Market in EMEA
      • Market Overview
      • Market Size and Forecast
        • Table Glioblastoma Multiforme Therapeutics Market in EMEA 2014-2019 ($ millions)
    • Glioblastoma Multiforme Therapeutics Market in APAC
      • Market Overview
      • Market Size and Forecast
        • Table Glioblastoma Multiforme Therapeutics Market in APAC 2014-2019 ($ millions)
        • Table Global Glioblastoma Multiforme Therapeutics Market by Geography 2014-2019
  • Buying Criteria
  • Pipeline Portfolio
    • Table Glioblastoma Multiforme: Pipeline Portfolio
    • Table Drug Candidates by Stage of Development (percentage)
  • Market Growth Drivers
    • Table Drivers of the Global Glioblastoma Multiforme Therapeutics Market
  • Drivers and their Impact
  • Market Challenges
    • Table Challenges of the Global Glioblastoma Multiforme Therapeutics Market
  • Impact of Drivers and Challenges
  • Market Trends
    • Table Trends in the Global Glioblastoma Multiforme Therapeutics Market
  • Trends and their Impact
  • Vendor Landscape
    • Competitive Scenario
      • Key News
      • Mergers and Acquisitions
    • Market Share Analysis 2014
      • Arbor Pharmaceuticals
      • Bristol-Myers Squibb
      • Eisai
      • F. Hoffmann-La Roche
      • Merck
    • Other and Possible Future Prominent Vendors
  • Key Vendor Analysis
    • Arbor Pharmaceuticals
      • Key Facts
      • Business Overview
      • Business Strategy
      • Recent Developments
      • SWOT Analysis
    • Bristol-Myers Squibb
      • Key Facts
      • Business Overview
      • Key Product Offerings
        • Table Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
      • Revenue by Geography
        • Table Bristol-Myers Squibb Co.: Geographical Segmentation by Revenue 2013
      • Business Strategy
      • Key Information
      • SWOT Analysis
    • Eisai
      • Key Facts
      • Business Overview
      • Comparison between Revenue, Operating Income, and Net Income
        • Table Eisai: Comparison between Revenue, Operating Income, and Net Income 2011-2013 ($ billions)
      • Sales by Geography
        • Table Eisai: Sales by Geography 2013 ($ billions)
      • Business Strategy
      • Key Information
      • SWOT Analysis
    • F. Hoffmann-La Roche
      • Key Facts
      • Business Overview
      • Business Segmentation
        • Table F. Hoffmann-La Roche: Business Segmentation2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
      • Sales by Geography
        • Table F. Hoffmann-La Roche: Sales by Geography 2013 (Pharmaceuticals Division)
        • Table F. Hoffmann-La Roche: Sales by Geography 2013 (Diagnostics Division)
      • Business Strategy
      • Key Information
      • SWOT Analysis
    • Merck
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2013
        • Table Merck: Business Segmentation by Revenue 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table Merck: Business Segmentation by Revenue 2012 and 2013 ($ billions)
      • Sales by Geography
        • Table Merck: Sales by Geography 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
  • Other Reports in this Series

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report